Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-101

While dystrophin protein signals were observed in the muscle
tissues of the treated mice, the results were inconclusive as the method used to analyse the
dystrophin levels was insufficiently sensitive, accordingly the muscle tissue is now to be reanalysed to assess dystrophin levels using a more sensitive assay method with the results of this
analysis anticipated in May.

I wonder if the area bolded (in hindsight) could have been spelt out a little better by management. For example, if we have any dystrophin at all... what does this mean? It seems we do have dystrophin.... which is perhaps inline with the microscopic dystro amounts from exon drugs, or perhaps a little more than that, or a lot more? As we know the dystro making drugs only make 1% so we're looking at a very small amount. How easy is that to see and confidently notate for someone to use as a yardstick to potentially spend a crapload of money on us.. I don't know. Perhaps this is where we are at and ...the market hates uncertainty.

For all we know the area bolded above could be a bumper prelude to a rocking announcement followup study. Any scientists care to have a go?